Latest News
Why Neurology Clinical Trials Need Purpose-Built AI
Each year on May 20, International Clinical Trials Day recognizes James Lind’s 1747 scurvy trial and the patients, clinicians, coordinators, sponsors and researchers who make clinical progress possible. It is also a moment to look honestly at where clinical research...
Latest News
What the Veppanu Approval Means for ESR1 Breast Cancer
The FDA's approval of Veppanu (vepdegestrant) marks the first regulatory clearance for a PROTAC in any disease area, and opens a new chapter in the treatment of ESR1-mutated advanced breast cancer. On 1 May 2026, the United States Food and Drug Administration approved...
Burnout in the Helping Profession: Why Healthcare Keeps Getting it Wrong
Across the life sciences sector, a quiet crisis is unfolding. Researchers, clinicians, nurses, and social workers describe feeling trapped in a cycle with no exit: outwardly productive, inwardly depleted. Burnout is not a new phenomenon, but the life sciences...
Agentic AI in Drug Discovery: Why Big Pharma is All in
When Eli Lilly signed a deal worth up to $2.75 billion with AI drug developer Insilico Medicine in March 2026, it was the latest in a cascade of nine-figure and ten-figure commitments from the world’s largest pharmaceutical companies to a single emerging technology....
Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis
Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
China Drug Trials Now Outpace the US. Here is What That Means
China has overtaken the United States in the annual number of drug clinical trials. It is a sentence that would have seemed implausible a decade ago. Today, it is simply fact, and the implications for drug development, global pharma strategy, and geopolitical...
Why Biopharma Must Invest in Novel Targets
Drug development continues to concentrate on a small set of well-known targets, creating a crowded landscape where many companies pursue similar pathways. While research into novel mechanisms continues, familiar targets often take priority, reflecting a cautious...
Weekly News Roundup | 18 May 2026
Life science news 18 May 2026: FDA leadership turmoil, a landmark Alzheimer's breakthrough and a $15 billion China licensing deal define a historic week for the global industry. The week of 10 to 17 May 2026 delivered a concentration of high-impact events across...
Biologics on the Brink: The Patent Cliff Facing Big Pharma
The global pharmaceutical industry is approaching what many analysts are calling the largest patent cliff biologics in its history. This pharma patent cliff biologics analysts have long anticipated is now arriving in force. Between 2025 and 2030, drugs collectively...
Clinical Trials Roundup | 15 May 2026
AstraZeneca's eneboparatide meets the Phase 3 CALYPSO primary endpoint in chronic hypoparathyroidism with full data presented at the European Congress of Endocrinology, Alkermes' LUMRYZ meets its primary endpoint in the Phase 3 REVITALYZ trial for idiopathic...
GLP-1 Receptor Agonists Explained: How They Work and Who They’re For
What Are GLP-1 Receptor Agonists? GLP-1 receptor agonists have become one of the most talked-about drug classes in modern medicine. Originally developed to treat type 2 diabetes, these medicines now carry approved indications spanning obesity, cardiovascular disease,...
Hallmarks of Ageing as a Framework: How the Research Field is Evolving
When López-Otín and colleagues published “The Hallmarks of Aging” in Cell in 2013, they did something the field of biogerontology had quietly needed for decades: they created a framework. Nine interconnected processes, from genomic instability and telomere attrition...
Biotech M&A 2026: Every $1B+ Deal so Far and What is Driving Them
The biotech M&A 2026 market has entered what many analysts are already calling a breakout year. In the first four months of 2026 alone, pharma and biotech companies have signed deals worth approximately $84 billion, and the pipeline of transactions shows no sign...
Muscular Dystrophy Has New Treatments. Patients Still Can’t Get Diagnosed
A generation of transformative therapies is arriving for Duchenne muscular dystrophy. Gene therapies have reached the clinic. Oral small molecules targeting the fundamental biology of the disease are entering clinical trials. Newborn screening programmes are being...
Beyond GLP-1: The Future of Obesity Care is Hybrid
The emergence of GLP-1 receptor agonists has fundamentally reshaped obesity treatment. For the first time, we are seeing consistent, clinically meaningful weight loss at scale, supported by robust clinical programs such as STEP and SURMOUNT (Wilding et al., 2021;...
Using AI to Translate Fragmented Evidence into Formulation Logic
Thesis Early-stage life science development is increasingly constrained not by lack of data, but by fragmented, multi-scale evidence that resists straightforward interpretation. AI systems can assist in structuring this complexity – through literature triage,...
First Alzheimer’s Biomarker Reversal Linked to Lyme Disease Treatment
Alzheimer’s disease (AD) represents a significant medical concern for all of us as we grow older, as the NIH has published that the average risk of dementia over 55 years old is now 42%. AD is presently affecting 6.9 million Americans aged 65 or older and is expected...
China Drug Trials Now Outpace the US. Here is What That Means
China has overtaken the United States in the annual number of drug clinical trials. It is a sentence that would have seemed implausible a decade ago. Today, it is simply fact, and the implications for drug development, global pharma strategy, and geopolitical...
Why Biopharma Must Invest in Novel Targets
Drug development continues to concentrate on a small set of well-known targets, creating a crowded landscape where many companies pursue similar pathways. While research into novel mechanisms continues, familiar targets often take priority, reflecting a cautious...
Weekly News Roundup | 18 May 2026
Life science news 18 May 2026: FDA leadership turmoil, a landmark Alzheimer's breakthrough and a $15 billion China licensing deal define a historic week for the global industry. The week of 10 to 17 May 2026 delivered a concentration of high-impact events across...
Biologics on the Brink: The Patent Cliff Facing Big Pharma
The global pharmaceutical industry is approaching what many analysts are calling the largest patent cliff biologics in its history. This pharma patent cliff biologics analysts have long anticipated is now arriving in force. Between 2025 and 2030, drugs collectively...
Clinical Trials Roundup | 15 May 2026
AstraZeneca's eneboparatide meets the Phase 3 CALYPSO primary endpoint in chronic hypoparathyroidism with full data presented at the European Congress of Endocrinology, Alkermes' LUMRYZ meets its primary endpoint in the Phase 3 REVITALYZ trial for idiopathic...
GLP-1 Receptor Agonists Explained: How They Work and Who They’re For
What Are GLP-1 Receptor Agonists? GLP-1 receptor agonists have become one of the most talked-about drug classes in modern medicine. Originally developed to treat type 2 diabetes, these medicines now carry approved indications spanning obesity, cardiovascular disease,...
Hallmarks of Ageing as a Framework: How the Research Field is Evolving
When López-Otín and colleagues published “The Hallmarks of Aging” in Cell in 2013, they did something the field of biogerontology had quietly needed for decades: they created a framework. Nine interconnected processes, from genomic instability and telomere attrition...
Biotech M&A 2026: Every $1B+ Deal so Far and What is Driving Them
The biotech M&A 2026 market has entered what many analysts are already calling a breakout year. In the first four months of 2026 alone, pharma and biotech companies have signed deals worth approximately $84 billion, and the pipeline of transactions shows no sign...
Muscular Dystrophy Has New Treatments. Patients Still Can’t Get Diagnosed
A generation of transformative therapies is arriving for Duchenne muscular dystrophy. Gene therapies have reached the clinic. Oral small molecules targeting the fundamental biology of the disease are entering clinical trials. Newborn screening programmes are being...
Beyond GLP-1: The Future of Obesity Care is Hybrid
The emergence of GLP-1 receptor agonists has fundamentally reshaped obesity treatment. For the first time, we are seeing consistent, clinically meaningful weight loss at scale, supported by robust clinical programs such as STEP and SURMOUNT (Wilding et al., 2021;...
Using AI to Translate Fragmented Evidence into Formulation Logic
Thesis Early-stage life science development is increasingly constrained not by lack of data, but by fragmented, multi-scale evidence that resists straightforward interpretation. AI systems can assist in structuring this complexity – through literature triage,...
First Alzheimer’s Biomarker Reversal Linked to Lyme Disease Treatment
Alzheimer’s disease (AD) represents a significant medical concern for all of us as we grow older, as the NIH has published that the average risk of dementia over 55 years old is now 42%. AD is presently affecting 6.9 million Americans aged 65 or older and is expected...
Featured Articles
Further News
Invisible Architect: How Infrastructure Drives Life Sciences Growth
In the high-stakes world of drug discovery and biomanufacturing, the spotlight typically shines on breakthrough modalities, venture rounds, and FDA milestones. Yet, behind every clinical success is a physical environment that either accelerated the science or quietly...
CagriSema: The Next Big Obesity Drug? What the Phase 3 Data Shows
The global obesity drug market is in the midst of its most competitive period in a generation. Since the approval of semaglutide as Wegovy and tirzepatide as Zepbound, pharmaceutical companies and investors have been watching closely for the next therapy capable of...
Weekly News Roundup | 11 May 2026
Life science news 11 May 2026: M&A momentum, artificial intelligence diagnostics and a record week for deal-making define an active seven days for the global life science industry. The week of 4 to 10 May 2026 produced a dense cluster of major acquisitions, a...
Why “Hot” Therapeutic Areas Break Traditional Benchmarks
In fast-moving areas like radiopharmaceuticals and precision immunology, the biggest portfolio risk is often not uncertainty itself, but false certainty created by mismatched benchmarks. As life sciences enters a more disciplined cycle, one pattern shows up across...
Is Photodisinfection the New Alternative to Traditional Antibiotics?
Few ideas in modern medicine are as unsettling as the prospect of a “post-antibiotic era.” For decades, antibiotics have underpinned infection control, transforming once-lethal diseases into manageable conditions. Yet their effectiveness is steadily eroding....
Orforglipron Approved: Inside the Oral GLP-1 Race
The obesity treatment landscape shifted decisively on 1 April 2026, when the US Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The decision marks the arrival of...
Clinical Trials Roundup | 8 May 2026
Cytokinetics’ aficamten meets dual primary endpoints in the pivotal Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy, Axsome Therapeutics secures FDA approval of AUVELITY as the first non-antipsychotic treatment for Alzheimer’s disease...
GSK Secures $1bn Rights to SiranBio siRNA Therapy
GSK has entered into an exclusive licensing agreement with Chinese biotech Suzhou Siran Biotechnology (SiranBio), securing global rights to the company's early-stage small interfering RNA (siRNA) therapy, SA030, in a deal worth up to $1.005 billion in potential...
From Wrist to Ward: Which Wearables Have Earned Clinical Trust
The wearable health technology market has expanded at a pace that regulators, clinicians, and patients have struggled to keep up with. Smartwatches, adhesive biosensors, continuous glucose monitors, and cardiac patches are now part of the fabric of daily life for...
Why Innovation in Oncology Diagnostics Is An Imperative We Must Prioritize
Not long ago, I spoke with a colleague, a mother named Kelley who has spent the past two years asking a question that increasingly reflects a broader challenge in oncology: If technologies exist to detect cancer earlier, why aren’t we dedicating more effort to support...
India, Brazil and Southeast Asia: The New Pharma Powerhouses
For most of the twentieth century, the global pharmaceutical industry operated on a straightforward geographic logic. Drugs were discovered and developed in North America and Western Europe, approved by the FDA and EMA, and then exported to the rest of the world. The...
Paediatric Trials: Why Children Remain Therapeutic Orphans
Children have long been described as therapeutic orphans. It is a term first used by the American paediatrician Harry Shirkey of the Children’s Hospital in Birmingham, Alabama, at a 1963 conference and formally published in 1968. Despite more than five decades of...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.